ClinicalTrials.gg
CompletedNCT02951182Updated Aug 28, 2020Results posted

A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis

A Phase 2 interventional study of TEZ and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 40 sites in 10 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-08-28.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing tezacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. tezacaftor · Cystic Fibrosis.

Enrollment
29th of 43
74 · median 100
Started
2016
with 5 others
Phase 2
8 of 43
none open now
Registered
12th of 43
by date
Lead sponsor
39 of 43
Vertex Pharmaceuticals Incorporated

Among the 43 studies testing tezacaftor in Cystic Fibrosis, this one is the 29th largest by enrollment, is one of 6 that started in 2016, is one of 8 in phase 2, and was the 12th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 43 studies testing tezacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tezacaftor

tezacaftor: first FDA approval 2024 (ALYFTREK), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing tezacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

This is a Phase 2, randomized, double-blind, placebo- and active-controlled, parallel group, multicenter study to evaluate the safety, tolerability, and efficacy of VX-440 in dual and triple combination with tezacaftor (TEZ; VX-661) and ivacaftor (IVA; VX-770) in subjects with cystic fibrosis (CF) who are homozygous for the F508del mutation of the CF transmembrane conductance regulator (CFTR) gene (F508del/F508del), or who are heterozygous for the F508del mutation and a minimal function (MF) CFTR mutation not likely to respond to TEZ and/or IVA therapy (F508del/MF).

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to comply with scheduled visits, treatment plan, study restrictions, laboratory tests, guidelines, and other study procedures.
  • To prevent pregnancy, female participants of and their male partners will be required to use pre-specified, highly effective methods of non-hormonal contraception. Male participants with female partners of childbearing potential will be required to use a condom.
  • Body weight ≥35 kg.
  • Sweat chloride value ≥60 mmol/L from test results obtained during screening.
  • Subjects must have an eligible CFTR genotype:

    • Heterozygous for F508del and a minimal function (MF) mutation known or predicted not to be responsive to TEZ and/or IVA.
    • Homozygous for F508del
  • Subjects must have an ≥40% and ≤90% of predicted normal for age, sex, and height at the Screening Visit
  • Stable CF disease as judged by the investigator.
  • Willing to remain on a stable CF medication regimen through the planned end of treatment or, if applicable, the Safety Follow up Visit.

Exclusion criteria

Exclusion Criteria:

  • History of any comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject.
  • History of cirrhosis with portal hypertension.
  • Risk factors for Torsade de Pointes
  • History of hemolysis.
  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency assessed at Screening.
  • abnormal laboratory values at screening
  • An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 28 days before the first dose of study drug.
  • Lung infection with organisms associated with a more rapid decline in pulmonary status
  • An acute illness not related to CF within 14 days before the first dose of study drug
  • A standard digital demonstrating >450 msec at screening.
  • History of solid organ or hematological transplantation.
  • History or evidence of cataract or lens opacity determined to be clinically significant by the ophthalmologist or optometrist based on the ophthalmologic examination during the Screening Period.
  • History of alcohol or drug abuse in the past year, including but not limited to, cannabis, cocaine, and opiates, as deemed by the investigator.
  • Ongoing or prior participation in an drug study, with certain exceptions. (e.g., ongoing participation in NCT02565914)
  • Use of commercially available CFTR modulator (e.g., Kalydeco, Orkambi) within 14 days before screening (applies only to the Heterozygous F508del/MF cohorts; does not apply to the Homozygous F508del/F508del Cohort).
  • Pregnant or nursing females: Females of must have a negative pregnancy test at screening and Day 1.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
74 participants (actual)

Study arms

  • Placebo comparator
    Part 1: Placebo - Cohort 1A and 1B Combined

    Participants received placebo matched to VX-440/TEZ/IVA as triple combination for 4 weeks.

    Drug: Matched Placebo

  • Experimental
    Part 1 Cohort 1A: Triple Combination (TC)

    Participants received VX-440 200 milligram (mg) every 12 hours (q12h)/TEZ 100 mg once daily (qd)/IVA 150 mg q12h as triple combination for 4 weeks.

    Drug: TEZ · Drug: IVA · Drug: VX-440

  • Experimental
    Part 1 Cohort 1B: TC Low Dose

    Participants received VX-440 200 mg q12h/TEZ 50 mg q12h/IVA 150 mg q12h as triple combination for 4 weeks.

    Drug: TEZ · Drug: IVA · Drug: VX-440

  • Experimental
    Part 1 Cohort 1B: TC High Dose

    Participants received VX-440 600 mg q12h/TEZ 50 mg q12h/IVA 300 mg q12h as triple combination for 4 weeks.

    Drug: TEZ · Drug: IVA · Drug: VX-440

  • Active comparator
    Part 2: TEZ/IVA

    Following a 4-week run-in period on TEZ 100 mg qd/IVA150 mg q12h, participants received placebo matched to VX-440 and TEZ 50 mg q12h/IVA 300 mg q12h for 4 weeks in treatment period and TEZ 100 mg qd/IVA150 mg q12h for 4 weeks in washout period.

    Drug: TEZ · Drug: IVA · Drug: Matched Placebo

  • Experimental
    Part 2: TC-2

    Following a 4-week run-in period on TEZ 100 mg qd/IVA150 mg q12h, participants received VX-440 600 mg q12h/ TEZ 50 mg q12h/IVA 300 mg q12h for 4 weeks for 4 weeks in treatment period and TEZ 100 mg qd/IVA150 mg q12h for 4 weeks in washout period.

    Drug: TEZ · Drug: IVA · Drug: VX-440

Interventions

  • DrugTEZ

    Also known as: tezacaftor, VX-661

  • DrugIVA

    Also known as: ivacaftor, VX-770

  • DrugVX-440
  • DrugMatched Placebo
06

What researchers measure

Primary outcomes

  1. Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From first dose of Study Drug in the Treatment Period through Safety Follow-up Visit (Up to Day 57 for Part 1 and Day 85 for Part 2)

  2. Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: From Baseline through Day 29

Secondary outcomes

  1. Absolute Change in Sweat Chloride Concentrations

    Sweat samples were collected using an approved collection device.

    Time frame: From Baseline through Day 29

  2. Relative Change in ppFEV1

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: From Baseline through Day 29

  3. Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

    The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

    Time frame: From Baseline at Day 29

  4. Pre-dose Plasma Concentration (Ctrough) of VX-440, TEZ, M1-TEZ, IVA and M1-IVA

    Time frame: Predose at Day 8, Day 15 and Day 29

07

Results

Posted Aug 28, 2020

Participant flow

Of the 74 participants enrolled (47 participants in Part 1 and 27 participants in Part 2), 1 participant in Part 2 discontinued in the Run-in Period because continuation criteria were not met and was not randomized in the Treatment Period. Therefore, only 73 participants are included in the results below.

Participant flow — Overall Study
MilestonePart 1: Placebo - Cohort 1A and 1B CombinedPart 1 Cohort 1A: Triple Combination (TC)Part 1 Cohort 1B: TC Low DosePart 1 Cohort 1B: TC High DosePart 2: TEZ/IVAPart 2: TC-2
Started119918620
Completed119918620
Not completed000000

Outcome measures

PrimarySafety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
From first dose of Study Drug in the Treatment Period through Safety Follow-up Visit (Up to Day 57 for Part 1 and Day 85 for Part 2)
Reported as:
Number · participants
Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsPart 1: Placebo - Cohort 1A and 1B CombinedPart 1 Cohort 1A: Triple Combination (TC)Part 1 Cohort 1B: TC Low DosePart 1 Cohort 1B: TC High DosePart 2: TEZ/IVAPart 2: TC-2
Participants with AEs99915615
Participants with SAEs000221
PrimaryAbsolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
From Baseline through Day 29
Reported as:
Least squares mean · percentage points
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
percentage pointsPart 1: Placebo - Cohort 1A and 1B CombinedPart 1: TC-1A/ TC-1B-low PooledPart 1 Cohort 1B: TC High DosePart 2: TEZ/IVAPart 2: TC-2
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)1.4 (-2.7 to 5.5)10.0 (6.9 to 13.2)12.0 (8.8 to 15.2)-2.5 (-7.2 to 2.2)9.5 (6.9 to 12.2)
Statistical analysis
  • Part 1: Placebo - Cohort 1A and 1B Combined vs Part 1: TC-1A/ TC-1B-low Pooled · Mixed-effects Model for Repeated Measure · p = 0.0016 · Least squares (ls) mean difference: 8.6 · 95% CI 3.5 to 13.8
  • Part 1: Placebo - Cohort 1A and 1B Combined vs Part 1 Cohort 1B: TC High Dose · Mixed-effects Model for Repeated Measure · p = 0.0001 · Least squares (ls) mean difference: 10.6 · 95% CI 5.5 to 15.8
  • Part 2: TEZ/IVA vs Part 2: TC-2 · Mixed-effects Model for Repeated Measure · p = 0.0001 · Least squares (ls) mean difference: 12.0 · 95% CI 6.7 to 17.4
SecondaryAbsolute Change in Sweat Chloride Concentrations

Sweat samples were collected using an approved collection device.

Time frame:
From Baseline through Day 29
Reported as:
Least squares mean · millimole per liter (mmol/L)
Absolute Change in Sweat Chloride Concentrations
millimole per liter (mmol/L)Part 1: Placebo - Cohort 1A and 1B CombinedPart 1: TC-1A/ TC-1B-low PooledPart 1 Cohort 1B: TC High DosePart 2: TEZ/IVAPart 2: TC-2
Absolute Change in Sweat Chloride Concentrations1.6 (-6.2 to 9.4)-20.7 (-26.6 to -14.7)-33.1 (-39.1 to -27.1)2.1 (-10.9 to 15.1)-31.3 (-38.6 to -24.1)
Statistical analysis
  • Part 1: Placebo - Cohort 1A and 1B Combined vs Part 1: TC-1A/ TC-1B-low Pooled · Least squares (ls) mean difference: -22.3 · 95% CI -32.1 to -12.4
  • Part 1: Placebo - Cohort 1A and 1B Combined vs Part 1 Cohort 1B: TC High Dose · Least squares (ls) mean difference: -34.7 · 95% CI -44.7 to -24.8
  • Part 2: TEZ/IVA vs Part 2: TC-2 · Least squares (ls) mean difference: -33.4 · 95% CI -48.5 to -18.3
SecondaryRelative Change in ppFEV1

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
From Baseline through Day 29
Reported as:
Least squares mean · percent change
Relative Change in ppFEV1
percent changePart 1: Placebo - Cohort 1A and 1B CombinedPart 1: TC-1A/ TC-1B-low PooledPart 1 Cohort 1B: TC High DosePart 2: TEZ/IVAPart 2: TC-2
Relative Change in ppFEV12.6 (-4.9 to 10.0)17.3 (11.5 to 23.2)21.7 (15.9 to 27.5)-3.4 (-11.4 to 4.6)16.6 (12.1 to 21.1)
Statistical analysis
  • Part 1: Placebo - Cohort 1A and 1B Combined vs Part 1: TC-1A/ TC-1B-low Pooled · Least squares (ls) mean difference: 14.8 · 95% CI 5.3 to 24.2
  • Part 1: Placebo - Cohort 1A and 1B Combined vs Part 1 Cohort 1B: TC High Dose · Least squares (ls) mean difference: 19.1 · 95% CI 9.7 to 28.6
  • Part 2: TEZ/IVA vs Part 2: TC-2 · Least squares (ls) mean difference: 20.0 · 95% CI 10.8 to 29.1
SecondaryAbsolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score

The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.

Time frame:
From Baseline at Day 29
Reported as:
Least squares mean · units on a scale
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score
units on a scalePart 1: Placebo - Cohort 1A and 1B CombinedPart 1: TC-1A/ TC-1B-low PooledPart 1 Cohort 1B: TC High DosePart 2: TEZ/IVAPart 2: TC-2
Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score2.2 (-6.2 to 10.6)18.3 (11.7 to 24.9)20.7 (14.2 to 27.1)-7.8 (-14.8 to -0.8)12.3 (8.7 to 16.0)
Statistical analysis
  • Part 1: Placebo - Cohort 1A and 1B Combined vs Part 1: TC-1A/ TC-1B-low Pooled · Least squares (ls) mean difference: 16.1 · 95% CI 5.4 to 26.8
  • Part 1: Placebo - Cohort 1A and 1B Combined vs Part 1 Cohort 1B: TC High Dose · Least squares (ls) mean difference: 18.5 · 95% CI 7.9 to 29.1
  • Part 2: TEZ/IVA vs Part 2: TC-2 · Least squares (ls) mean difference: 20.2 · 95% CI 11.9 to 28.4
SecondaryPre-dose Plasma Concentration (Ctrough) of VX-440, TEZ, M1-TEZ, IVA and M1-IVA
Time frame:
Predose at Day 8, Day 15 and Day 29
Reported as:
Mean · nanogram per milliliter (ng/mL)
Pre-dose Plasma Concentration (Ctrough) of VX-440, TEZ, M1-TEZ, IVA and M1-IVA
nanogram per milliliter (ng/mL)Part 1 Cohort 1A: Triple Combination (TC)Part 1 Cohort 1B: TC Low DosePart 1 Cohort 1B: TC High DosePart 2: TEZ/IVAPart 2: TC-2
VX-440: Day 81670 ± 1910————
VX-440: Day 151840 ± 14601120 ± 7078540 ± 6850—12900 ± 9940
VX-440: Day 291090 ± 10101440 ± 18706650 ± 3500—10300 ± 7340
TEZ: Day 8810 ± 323————
TEZ: Day 15749 ± 2711070 ± 422928 ± 5582240 ± 10101250 ± 837
TEZ: Day 29761 ± 3201040 ± 659846 ± 5141420 ± 565893 ± 579
M1-TEZ: Day 83160 ± 645————
M1-TEZ: Day 153490 ± 4864610 ± 11703400 ± 12704640 ± 17303940 ± 1200
M1-TEZ: Day 293560 ± 3784180 ± 19503050 ± 12604060 ± 15603280 ± 1230
IVA: Day 8281 ± 167————
IVA: Day 15245 ± 92.7192 ± 97.0233 ± 1491040 ± 352380 ± 312
IVA: Day 29209 ± 112164 ± 108219 ± 139902 ± 344290 ± 263
M1-IVA: Day 8795 ± 327————
M1-IVA: Day 15854 ± 427566 ± 245850 ± 5461640 ± 2181220 ± 796
M1-IVA: Day 29702 ± 372520 ± 338792 ± 4661580 ± 7641080 ± 732

Adverse events

Collected over From first dose of Study Drug in the Treatment Period through Safety Follow-up Visit (Up to Day 57 for Part 1 and Day 85 for Part 2). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Placebo - Cohort 1A and 1B Combined0/11 (0%)0/11 (0%)9/11 (81.8%)
Part 1 Cohort 1A: Triple Combination (TC)0/9 (0%)0/9 (0%)9/9 (100%)
Part 1 Cohort 1B: TC Low Dose0/9 (0%)0/9 (0%)9/9 (100%)
Part 1 Cohort 1B: TC High Dose0/18 (0%)2/18 (11.1%)15/18 (83.3%)
Part 2: TEZ/IVA0/6 (0%)2/6 (33.3%)5/6 (83.3%)
Part 2: TC-20/20 (0%)1/20 (5%)15/20 (75%)
Most frequent serious events
Most frequent serious events
EventPart 1: Placebo - Cohort 1A and 1B CombinedPart 1 Cohort 1A: Triple Combination (TC)Part 1 Cohort 1B: TC Low DosePart 1 Cohort 1B: TC High DosePart 2: TEZ/IVAPart 2: TC-2
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations0/110/90/91/181/61/20
Adjustment disorderPsychiatric disorders0/110/90/90/181/60/20
Distal intestinal obstruction syndromeGastrointestinal disorders0/110/90/91/180/60/20
Most frequent other events
Showing 10 of 103
Most frequent other events
EventPart 1: Placebo - Cohort 1A and 1B CombinedPart 1 Cohort 1A: Triple Combination (TC)Part 1 Cohort 1B: TC Low DosePart 1 Cohort 1B: TC High DosePart 2: TEZ/IVAPart 2: TC-2
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations2/116/90/92/180/62/20
CoughRespiratory, thoracic and mediastinal disorders4/113/91/91/180/65/20
Viral upper respiratory tract infectionInfections and infestations1/110/92/92/182/61/20
Sputum increasedRespiratory, thoracic and mediastinal disorders3/111/91/91/181/63/20
Upper respiratory tract infectionInfections and infestations0/112/90/92/180/62/20
FatigueGeneral disorders0/110/92/90/180/60/20
DiarrhoeaGastrointestinal disorders1/111/91/92/180/64/20
DyspnoeaRespiratory, thoracic and mediastinal disorders2/110/90/90/180/61/20
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/110/90/90/180/61/20
Respiration abnormalRespiratory, thoracic and mediastinal disorders2/110/90/90/180/61/20

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part 1: Placebo - Cohort 1A and 1B CombinedPart 1 Cohort 1A: Triple Combination (TC)Part 1 Cohort 1B: TC Low DosePart 1 Cohort 1B: TC High DosePart 2: TEZ/IVAPart 2: TC-2Total
<=18 years0000000
Between 18 and 65 years11991862073
>=65 years0000000
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Placebo - Cohort 1A and 1B CombinedPart 1 Cohort 1A: Triple Combination (TC)Part 1 Cohort 1B: TC Low DosePart 1 Cohort 1B: TC High DosePart 2: TEZ/IVAPart 2: TC-2Total
Female21310411
Male9861761662
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: Placebo - Cohort 1A and 1B CombinedPart 1 Cohort 1A: Triple Combination (TC)Part 1 Cohort 1B: TC Low DosePart 1 Cohort 1B: TC High DosePart 2: TEZ/IVAPart 2: TC-2Total
Hispanic or Latino1010013
Not Hispanic or Latino10981761868
Unknown or Not Reported0001012
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Placebo - Cohort 1A and 1B CombinedPart 1 Cohort 1A: Triple Combination (TC)Part 1 Cohort 1B: TC Low DosePart 1 Cohort 1B: TC High DosePart 2: TEZ/IVAPart 2: TC-2Total
American Indian or Alaska Native0000000
Asian0000000
Native Hawaiian or Other Pacific Islander0000000
Black or African American0000000
White10991862072
More than one race0000000
Unknown or Not Reported1000001
08

Study locations

40 sites
  • The Arizona Board of Regents on behalf of the University of Arizona
    Tucson, Arizona, United States
  • Stanford University
    Palo Alto, California, United States
  • University of California
    San Francisco, California, United States
  • National Jewish Health
    Denver, Colorado, United States
  • Joe Di Maggio Cystic Fibrosis & Pulmonary Center
    Hollywood, Florida, United States
  • Central Florida Pulmonary Group
    Orlando, Florida, United States
  • St. Luke's CF Center of Idaho
    Boise, Idaho, United States
  • Cystic Fibrosis Center of Chicago
    Glenview, Illinois, United States
  • The Johns Hopkins Hospital
    Baltimore, Maryland, United States
  • Boston Children's Hospital
    Boston, Massachusetts, United States
  • Massachusetts General Hospital Cystic Fibrosis Center
    Boston, Massachusetts, United States
  • University of Minnesota
    Minneapolis, Minnesota, United States
  • New York Medical College
    Hawthorne, New York, United States
  • Long Island Jewish Medical Center
    New Hyde Park, New York, United States
  • Columbia University Medical Center
    New York, New York, United States
  • Nationwide Children's Hospital
    Columbus, Ohio, United States
  • Respiratory Diseases of Children and Adolescents
    Oklahoma City, Oklahoma, United States
  • UPMC OSPARS Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania, United States
  • Sanford Children's Specialty Clinic Sanford Research USD
    Sioux Falls, South Dakota, United States
  • The University of Texas Southwestern Center
    Dallas, Texas, United States
  • Children's Hospital of the Kings Daughters
    Norfolk, Virginia, United States
  • Seattle Children's Hospital
    Seattle, Washington, United States
  • Royal Adelaide Hospital
    Adelaide, Australia
  • Prince Charles Hospital
    Chermside, Australia
  • John Hunter Hospital & Hunter Medical Research Institute
    New Lambton Heights, Australia
  • Medizinische Universitat Innsbruck
    Innsbruck, Austria
  • Universitair Ziekenhuis Brussel
    Brussels, Belgium
  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
    Leuven, Belgium
  • St. Paul's Hopsital
    Vancouver, British Columbia, Canada
  • St. Michael's Hospital
    Toronto, Ontario, Canada
  • Juliane Marie Center, Righospitalet
    Copenhagen, Denmark
  • Mukeviszidose-Zentrum am Universtitatsklinikum Jena
    Jena, Germany
  • University Hospital Cologne
    Koeln, Germany
  • Pneumologische Praxis Pasing
    Muenchen, Germany
  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
    Milano, Italy
  • Hospital Universitari Vall d´Hebron Servicio de Broncoscopia
    Barcelona, Spain
  • Hospital Universitario Virgen del Rocio
    Seville, Spain
  • Heart of England NHS Foundation Trust
    Birmingham, United Kingdom
  • Royal Brompton & Harefield NHS Foundation Trust, Royal Brompton Hospital
    London, United Kingdom
  • Southampton University Hospitals NHS Foundation Trust
    Southampton, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in Aug 2017, 10 months.

Results were first posted in Aug 2020, 3 years after primary completion. A results delay was requested in Aug 2018.

Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 10 months is below that.

Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2016
First posted
Nov 1, 2016
StartActual
Oct 2016
Primary completionActual
Aug 2017
CompletionActual
Aug 2017
Results delay requested
Aug 13, 2018
Results first posted
Aug 28, 2020
Last update
Aug 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02951182
Responsible party
Sponsor
First posted
Nov 1, 2016
Start date
Oct 2016
Primary completion
Aug 2017
Completion
Aug 2017
Results posted
Aug 28, 2020
Last update
Aug 28, 2020

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tezacaftor · Ivacaftor

Start the discussion